OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CESSA.TE50

Cessatech A/S

PharmaceuticalsVerified

Cessatech A/S has a fully diluted share count of 13,447,505 shares, with no difference between basic and diluted shares outstanding, indicating no dilution pressure from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Cessatech A/S, as the valuation snapshot does not include data on return on invested capital (ROIC), gross margins, or operating margins. Without these metrics, it is not possible to compare the company's performance to industry_config preferred metrics or cohort medians. Cessatech A/S does not disclose segment or geographic revenue breakdowns in the available data, making it impossible to assess revenue concentration or geographic exposure. This lack of transparency limits the ability to evaluate the company's diversification and risk profile. Growth trajectory data is also unavailable, as the outlook section does not provide numeric deltas or revenue history for the current or next fiscal year. This absence of forward-looking guidance and historical performance data hinders the ability to assess the company's growth potential. Risk factors include the inability to assess liquidity risk, which is a critical concern for investors. Additionally, the absence of balance-sheet data and going-concern language in source documents raises questions about the company's financial health and operational continuity. Recent events, including filings and transcripts, are not disclosed in the available data, preventing an analysis of the company's recent strategic moves or financial disclosures.

30-day price · CESSA.TE+0.70 (+4.4%)
Low$15.80High$21.20Close$16.50As of13 May, 00:00 UTC
Profile
CompanyCessatech A/S
TickerCESSA.TE
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Cessatech A/S has a fully diluted share count of 13,447,505 shares, with no difference between basic and diluted shares outstanding, indicating no dilution pressure from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Cessatech A/S, as the valuation snapshot does not include data on return on invested capital (ROIC), gross margins, or operating margins. Without these metrics, it is not possible to compare the company's performance to industry_config preferred metrics or cohort medians. Cessatech A/S does not disclose segment or geographic revenue breakdowns in the available data, making it impossible to assess revenue concentration or geographic exposure. This lack of transparency limits the ability to evaluate the company's diversification and risk profile. Growth trajectory data is also unavailable, as the outlook section does not provide numeric deltas or revenue history for the current or next fiscal year. This absence of forward-looking guidance and historical performance data hinders the ability to assess the company's growth potential. Risk factors include the inability to assess liquidity risk, which is a critical concern for investors. Additionally, the absence of balance-sheet data and going-concern language in source documents raises questions about the company's financial health and operational continuity. Recent events, including filings and transcripts, are not disclosed in the available data, preventing an analysis of the company's recent strategic moves or financial disclosures.
Key takeaways
  • Cessatech A/S has no dilution pressure from stock options or convertible instruments, as basic and diluted shares are equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • Profitability metrics such as ROIC and margins are not available, limiting the ability to compare performance to industry benchmarks.
  • No segment or geographic revenue data is disclosed, making it difficult to assess diversification and risk exposure.
  • Growth trajectory and recent events are not disclosed, reducing visibility into the company's strategic direction and performance.
  • --
  • **RATIONALES**:
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2
FY-1
FY0
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2
FY-1
FY0
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricCESSA.TEActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:19 UTC#eb469452
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 15:12 UTCJob: 2ce8e7bd